Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. The firm is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.
Follow-Up Questions
Cynata Therapeutics Ltd (CYYNF)'in P/E oranı nedir?
Cynata Therapeutics Ltd 'in P/E oranı N/A 'dir
Cynata Therapeutics Ltd 'in CEO'su kimdir?
Dr. Kilian Kelly 2019 'den beri şirketle birlikte olan Cynata Therapeutics Ltd 'in Chief Executive Officer 'ıdır.
CYYNF hissesinin fiyat performansı nasıl?
CYYNF 'in mevcut fiyatı 0.118 'dir, son işlem günde 0% decreased etti.
Cynata Therapeutics Ltd için ana iş temaları veya sektörler nelerdir?
Cynata Therapeutics Ltd Biotechnology endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 0 analist Cynata Therapeutics Ltd için analist derecelendirmeleri gerçekleştirdi, bunlar 1 güçlü al, 3 al, 1 tut, 0 sat ve 1 güçlü sat içermektedir
